By Fineline Cube China’s National Medical Products Administration (NMPA) issued the Catalog of Reference Listed Drugs for Generic Drugs (108th Batch) on Aug. 24, 2026. The latest release adds 17 new drug specifications to the catalog and provides supplementary updates for 28 specifications from previous batches, further refining the reference standards that govern generic drug development in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Document | Catalog of Reference Listed Drugs for Generic Drugs |
| Batch | 108th Batch |
| New Specifications Added | 17 |
| Supplementary Updates | 28 specifications from prior batches |
| Issue Date | 24 Aug 2026 |
Catalog Significance
- Reference Listed Drugs (RLDs): The catalog designates the originator or benchmark products against which Chinese generic applicants must demonstrate bioequivalence and quality consistency.
- Expanding Scope: The addition of 17 new specifications broadens the range of eligible reference products, signaling continued regulatory effort to align China’s generic approval framework with international standards.
- Supplementary Updates: The 28 updated entries from earlier batches typically reflect refined technical specifications, sourcing information or administrative corrections that help streamline generic development programs.
Industry Implications
- For Generic Developers: Newly listed RLDs clarify development pathways for additional products, reducing uncertainty for companies planning bioequivalence studies and Abbreviated New Drug Applications in China.
- For Market Competition: An expanded and updated catalog supports faster entry of quality generics, which can intensify price competition and improve patient access to essential therapies.
- Regulatory Trajectory: The NMPA continues its steady cadence of catalog releases as part of a broader reform agenda aimed at raising generic quality and accelerating drug availability in the world’s second‑largest pharmaceutical market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implications of the 108th Batch catalog for generic drug development and market dynamics in China. Actual outcomes may differ due to regulatory developments, approval timelines and competitive factors.-Fineline Info & Tech